Inhaled Delivery Systems for the Treatment of Asthma and COPD

Description

Inhaled therapies form the cornerstone for treatment of patients with asthma and COPD. Evolving technology has resulted in availability of a wide range of devices for delivery of inhaled drugs. The four different delivery systems -- pressurized metered-dose inhalers, slow mist inhalers, dry powder inhalers, and nebulizers -- are unique in design and require distinct inhalational instructions for correct use. This book provides current information about inhalation devices, including their advantages and disadvantages, with guidance for optimal techniques of use. The book emphasizes appropriate selection of inhalation devices based on patient and health care professional factors as well as device attributes that allow selection of the right medication in the right inhalation device at the right time for the right patient. Key Features: • Addresses the objective of precision medicine – the right medication in the right inhaler device at the right time. • Inputs by international thought leaders who have published widely on inhaled medications and/or inhaled delivery systems for clinicians, trainees and respiratory therapists. • Discusses the development of audio-based systems and smart inhalers for patient monitoring. Cover Half Title Title Page Copyright Page Contents Foreword About the Editors List of Contributors Introduction 1. Principles of Inhaled Therapy 2. Goals of Pharmacotherapy for Asthma and COPD 3. Pressurized Metered-Dose Inhalers (pMDI) 4. Spacers and Valved Holding Chambers 5. Slow Mist Inhalers 6. Dry Powder Inhalers 7. Digital Inhalers for the Management of Obstructive Lung Diseases 8. Nebulizers 9. Inhalation Therapy in Infants and Children 10. Selection of Inhaler Delivery System for Adult Outpatients 11. Inhalation Therapy in the Intensive Care Unit 12. Inhaled Therapy for Other Respiratory Diseases: Cystic Fibrosis and Non-cystic Fibrosis Bronchiectasis 13. Inhaled Therapy for Other Respiratory Diseases: Pulmonary Hypertension 14. Regulatory Considerations Related to Inhaled Delivery Systems Index